PrEPVacc welcomes results of HPTN 084 injectable PrEP study

PrEPVacc investigators have welcomed the announcement of the interim analysis of the HIV Prevention Trials Network (HPTN) 084 study into the efficacy of long-acting cabotegratvir for HIV prevention in women.

HPTN 084’s independent data safety monitoring board recommended the early unblinding of the study after it was shown that cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis in women.

“This is exciting news for the HIV prevention landscape and a much eagerly anticipated milestone in our HIV Prevention journey in Africa. We feel triumphant and relieved that we could achieve this outcome that will positively impact HIV prevention for women especially in Africa,” said Dr Nishanta Singh, PrEPVacc Site PI at South African Medical Research Council’s HIV Prevention Research Unit in Durban, South Africa. “Three SAMRC sites have participated in the HPTN 084 study, including the site where we will be running the PrEPVacc trial in South Africa, at Verulam in Durban.” The PI thanked the participants, community and the research team for their great contribution to HIV prevention options for women.

Professor Sheena McCormack, PrEPVacc Project Lead, congratulated all the investigators involved in HPTN 084 and thanked all the participants who had stepped forward to advance HIV prevention research. “This is a historic moment for all but especially women who can see a future where they can choose what to use to protect themselves against HIV – a pill, a ring, an injection – whatever suits them best at that particular time in their lives,“ said Professor McCormack.